The American Academy of Veterinary Pharmacology and Therapeutics (AAVPT) is announcing the Veterinary Drug Regulatory Life Cycle Course (VDRLC) that will be held in Potomac, MD from February 28 to March 04, 2011. Registration that was scheduled to start Monday, November 8th at 1 pm EST is delayed due to technical difficulties (AAVPT is using a web-based registration system). The new date for the start of registration is Wednesday, November 10th at 1 pm EST. Also, please note that registration will close promptly on December 8th at 11 pm EST. Registration is limited to up to 100 participants, so please sign up early.
Go to http://a3.acteva.com/orderbooking/go/aavpt to register for this course. The cost of registration (full 5 days) is $750. The website will direct you on how to register for the course and reserve your hotel accommodations at the Bolger Center.
The VDRLC course is intended to provide a comprehensive overview of FDA CVM regulatory processes for the approval of new animal drugs and post-approval surveillance/compliance of marketed drugs. This week-long course will cover topics related to current policies, procedures, and standards across all technical sections of the drug approval process, and all other aspects of the veterinary drug life-cycle. It will introduce the audience to all of CVM’s groups and activities and provide interactions with CVM scientists across various offices and divisions.
The course content is targeted to industry and academic stakeholders who are interested in understanding the regulatory science of veterinary drug development. Scientists in all areas of drug research and development, manufacturing and clinical testing may all benefit from taking this course (from bench scientists to regulatory managers and R&D researchers to veterinary clinicians).
The course covers topics at the operational and strategic level with plenty of opportunity for audience questions and discussion after each topic. However, in the interest of time and in order to address questions of common interest, audience participants are asked to limit questions to topics of benefit to all attendees. Questions on confidential material or specific drug applications are not considered appropriate for this venue.